Australia markets closed

ImpediMed Limited (IPD.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.09000.0000 (0.00%)
At close: 04:10PM AEST

ImpediMed Limited

50 Parker Court
Unit 1
Pinkenba, QLD 4008
Australia
61 7 3860 3700
https://www.impedimed.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees76

Key executives

NameTitlePayExercisedYear born
Mr. Shashi TripathiChief Operating Officer642.83kN/AN/A
Dr. Parmjot Bains M.D.MD, Interim CEO & DirectorN/AN/AN/A
Mr. McGregor Grant BEc, C.A., FCIS, GAICDInterim CFO & Executive DirectorN/AN/AN/A
Mr. Dennis SchlahtSenior Vice President of R&D and Technology478.63kN/AN/A
Lisa PromVice President of SalesN/AN/AN/A
Ms. Joann YaoChief Strategy OfficerN/AN/AN/A
Dr. Steven Chen M.B.A., M.D.Chief Medical CenterN/AN/AN/A
Ms. Leanne Ralph AAICD, ACIS, BBusCompany SecretaryN/AN/AN/A
Dr. Walton A. TaylorMedical DirectorN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

Corporate governance

ImpediMed Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.